Monitor for updates on the Israel MAA review outcome within the 180-working-day window, as approval could serve as a regulatory pathway template for other non-U.S. markets and catalyze further international submissions.
Price Chart
Executive Summary
Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Symvess) has been accepted by Israel's Ministry of Health for review, with a 180-working-day timeline due to prior FDA approval. This marks a key step in the company's planned international expansion of Symvess for arterial trauma repair.
Key Facts
- Israel Ministry of Health accepted Humacyte's MAA for Symvess (ATEV) for arterial trauma repair.
- Review period set at 180 working days, accelerated due to existing FDA approval in the U.S.
- This is part of Humacyte's strategy to expand Symvess globally beyond the U.S.
- Symvess received FDA approval in December 2024 for extremity vascular trauma.
- Additional late-stage trials ongoing for AV access and peripheral artery disease.
Financial Impact
Potential expansion into international markets could significantly increase revenue base; exact financial impact depends on approval outcome and reimbursement.
Risk Factors
- Regulatory delays or rejection outside the U.S. despite FDA precedent.
- Commercial execution risk in scaling manufacturing and market adoption internationally.
- Dependence on third-party reimbursement for market uptake.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4460 (+1.36%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4460 (−39.31%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4460 (−32.93%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4460 (−32.93%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4460 (−37.88%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4460 (−57.73%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4460 (+57.73%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4460 (+58.70%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4460 (+58.70%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4460 (−58.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers